India’s Insulin Market Set For Sparks As Two Large Players Challenge The Dominance Of Sanofi-Aventis’ Lantus
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - For nearly a decade, the world's fourth-largest drug maker, Sanofi-Aventis, has had a free play in India in marketing its world-famous insulin brand Lantus, the only long-acting basal insulin, widely prescribed for its ability to slowly release insulin into the body. Now that could change as two large Indian players, Wockhardt and Biocon, are looking at chipping away some of this lucrative and growing market through their own brand launches